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We describe emergomycosis in a patient in Uganda with 
HIV infection. We tested a formalin-fixed, paraffin-embed-
ded skin biopsy to identify Emergomyces pasteurianus or 
a closely related pathogen by sequencing broad-range fun-
gal PCR amplicons. Results suggest that emergomycosis 
is more widespread and genetically diverse than previously 
documented. PCR on tissue blocks may help clarify emer-
gomycosis epidemiology. 
Emergomycosis is a fungal infection caused by fungi of the newly described genus Emergomyces, of the order 
Onygenales, which includes obligate fungal pathogens, 
such as Histoplasma, Blastomyces, and Paracoccidioides 
(1). Emergomycosis manifests after dissemination to the 
lungs and skin; it is associated with 50% mortality. Most 
cases of emergomycosis have been reported in persons 
with HIV from South Africa infected with E. africanus, 
the DNA of which has been amplified from soil there (2). 
Emergomycosis from E. orientalis or E. canadensis infec-
tion has been identified in limited geographic areas. 
In contrast, E. pasteurianus infections have been 
widely documented in Asia, Europe, and South Africa (Ap-
pendix Table 2) (2). E. pasteurianus infections were first 
described in 1998 in a patient in Italy with HIV infection 
and skin lesions (3). The isolate was initially placed in the 
genus Emmonsia because of the similarity of the ribosom-
al large subunit genes. The new genus Emergomyces was 
suggested by Dukik et al. to distinguish fungi that produce 
small yeasts in host tissues, comparable to Histoplasma in-
stead of the adiaspores found in Emmonsia (4). We report 
a case of E. pasteurianus infection in a patient in Uganda 
with HIV infection.
A 38-year-old woman from Rwanda sought treatment 
in Uganda for a 3-month history of disseminated skin le-
sions, nodules, papules, and ulcers (Figure). A chest radio-
graph revealed no signs of disease. The woman was living 
in southwestern Uganda, working as a trader. She reported 
no travel except for a short visit to Dubai 5 years earlier. 
She had also been diagnosed with HIV 5 years earlier. She 
was treated for HIV with zidovudine, lamivudine, and ne-
virapine. CD4 lymphocyte count was 140 cells/µL. HIV 
viral load testing was not performed. 
A skin biopsy was taken, but fungal isolation was 
not performed because laboratorians lacked the necessary 
equipment. As therapy for emergomycosis, experts suggest 
amphotericin B, which was not available for the patient, 
followed by oral triazoles (2). The patient was started on 
fluconazole (400 mg 1×/d) for suspected cutaneous cryp-
tococcosis. Histopathology showed narrow budding yeast 
cells (2–4 µm) (Figure). Because skin lesions increased 
during 6 weeks of fluconazole and antiretroviral treatments, 
treatment was changed to itraconazole (400 mg 2×/d). Le-
sions decreased markedly within 8 weeks, which we con-
sidered the key finding suggesting treatment response. No 
follow-up data are available beyond this point. As reported 
by Dukik et al., in vitro resistance testing of Emergomy-
ces documents activity of itraconazole, voriconazole, and 
posaconazole, but not fluconazole (5). 
In Germany, DNA was extracted from the formalin-
fixed, paraffin-embedded (FFPE) skin biopsy as previously 
described (6). Fungal DNA was amplified by 2 broad-range 
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Figure. Imaging from 
investigation of emergomycosis 
in a 38-year-old woman from 
Rwanda with HIV infection 
living in Uganda. A) Skin lesion 
on face. B) Histopathology of 
skin biopsy specimen (Grocott 
stain) showing multiple budding 
yeast cells (2–3 µm), mostly  
in clusters. Scale bar indicates 
5 µm.
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PCR assays targeting a region of the 28S and the internal 
transcribed spacer (ITS) 2 regions of the fungal ribosomal 
RNA genes. Sanger sequencing of the PCR amplicons re-
vealed 365-bp and 273-bp sequences (Appendix, https://
wwwnc.cdc.gov/EID/article/25/9/18-1234-App1.pdf). A 
BLAST search (https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
revealed Paracoccidioides lutzii (98.6% pairwise iden-
tity) and E. pasteurianus (98.9% pairwise identity) to be 
the closest matches for the 28S and ITS2 amplicons. Be-
cause no generally accepted pairwise identity break points 
for fungal species identification are available and sequence 
data for the region amplified by the 28S assay are lack-
ing for many fungi, we sequenced the amplicons of the 2 
broad-range PCR assays from fungi of the family Ajello-
mycetaceae and of the species Coccidioides immitis (Ap-
pendix Table 2). Phylogenetic analysis of the concatenated 
sequences of both broad-range PCR assays suggested that 
the patient was infected with E. pasteurianus or a closely 
related species (Appendix Figure). 
Identification of fungi from pathology blocks may 
be used to investigate the etiology of mycosis and define 
endemic regions of fungal pathogens. However, species 
identification by histopathology is limited and the optimal 
molecular identification strategy remains to be defined. 
Amplification of fungal DNA from FFPE tissue is restrict-
ed by amplicon length, PCR inhibition, an excess of host 
DNA, and contaminating fungal DNA (7). The broad-range 
assays we used were introduced to amplify fungal DNA 
from an excess of host DNA. They have been successfully 
applied on FFPE tissue before (6,8). 
The ITS2 assay targets a diverse, noncoding region 
well represented in public databases. However, variable 
amplicon length (200–300 bp) suggests that detection lim-
its may vary for different fungi and phylogenetic analy-
sis may be impaired. In contrast, the 28S assay amplifies 
a more conserved coding region (330–350 bp). Whereas 
identification of a genus may be achieved, species resolu-
tion within a genus may not be possible and sequences of 
this region are underrepresented in public databases (4,6). 
Our results suggest that emergomycosis is more wide-
spread and genetically diverse than previously documented. 
This case suggests that using broad-range fungal PCR assays 
with specific PCR assays to target prevalent pathogens may 
be a successful approach for identifying fungal etiology from 
pathology blocks and defining the epidemiology of emergo-
mycosis and related infections.
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